Opioids and Cannabinoids for Neurologic Pain: What Neurologists Need to Know in 2024

A CME narrative review from the American Academy of Neurology synthesizes evolving guidelines, clinical trial evidence, and risk-mitigation strategies for opioid and cannabinoid use in neuropathic and chronic pain, framing a practical decision-making approach for neurologists navigating two high-interest and high-risk therapeutic areas.

Why This Matters

Chronic neuropathic pain affects millions of patients and remains one of the most difficult conditions to manage effectively. The opioid crisis reshaped prescribing culture, but the pendulum swing toward rapid opioid discontinuation has itself produced measurable harm, including overdose deaths and mental health crises. Meanwhile, cannabinoids have entered clinical conversation with increasing regulatory complexity and patient demand, yet without the robust evidence base clinicians need. A structured synthesis of the current landscape, published in the AAN’s continuing education journal, arrives at a moment when both under-treatment and over-treatment of pain carry serious consequences.

Clinical Summary

This narrative CME review, published in Continuum (October 2024, Volume 30, Issue 5), examines the evidence base for opioid and cannabinoid therapies in chronic and neuropathic pain from the perspective of practicing neurologists. The review traces the historical arc of opioid prescribing from the liberalization of the 1990s through the opioid crisis and subsequent guideline reforms, grounding the discussion in the biology of mu-opioid receptor activation and the phenomena of tolerance, hyperalgesia, and physical dependence that complicate long-term use. It also introduces the endocannabinoid system and the mechanistic rationale for cannabinoid analgesia in neuropathic conditions, noting that CB1 and CB2 receptor modulation may offer analgesic and anti-inflammatory effects through pathways distinct from opioid signaling.

Key findings from cited evidence include a meta-analysis of 96 randomized controlled trials (n=26,169) showing that opioids produce statistically significant but clinically small improvements in pain and physical function over one to six months for chronic noncancer pain, with benefits no greater than nonopioid alternatives. A 2023 blinded RCT found opioids provided no added benefit over nonopioid care for acute low back and neck pain and were associated with slightly worse outcomes and increased misuse risk. Short-term opioid use (four to twelve weeks) showed modest efficacy for postherpetic neuralgia and select peripheral neuropathies, but evidence was insufficient for most other neuropathic diagnoses. The review emphasizes that abrupt opioid tapering in patients already on long-term therapy is associated with illicit drug use, emergency hospitalizations, and increased mortality. Cannabinoids demonstrated evidence of efficacy in select neuropathic pain populations, though this portion of the review was only partially available for analysis. The authors frame both therapeutic areas as requiring further high-quality trials before broad clinical recommendations can be confidently issued.

Dr. Caplan’s Take

This review captures the uncomfortable tension that every clinician managing chronic pain lives with daily. The evidence is clear that long-term opioids rarely deliver what patients hope for in neuropathic pain, and the risk profile is genuinely concerning. But the equally important message here, one that got lost during the most aggressive phase of prescribing reform, is that forcing patients off established opioid therapy without careful individualized planning can be just as dangerous. Patients ask me about both opioids and cannabis regularly, and an honest response requires acknowledging that neither currently has the evidence base to serve as a reliable long-term solution for most neuropathic pain syndromes.

In practice, I approach opioid-naive patients with a clear nonopioid-first framework and invest heavily in multimodal strategies, including physical rehabilitation, neuromodulation, and appropriate first-line pharmacotherapy. For patients already on long-term opioids, I follow the CDC 2022 guidance emphasizing gradual, patient-centered tapering only when clinically appropriate, never abruptly. Regarding cannabinoids, I discuss them openly with patients while being transparent about the investigational nature of the evidence and the regulatory uncertainty. The goal is always harm reduction paired with honest expectation-setting.

Clinical Perspective

This review sits at a critical inflection point in the research arc for pain management. It confirms the now well-established position of the CDC 2022 and VA/DoD 2022 guidelines that long-term opioid therapy should generally not be initiated for chronic noncancer or neuropathic pain. It also reinforces the growing body of evidence that the harms of abrupt discontinuation were underappreciated during early guideline implementation. For patient-facing conversations, clinicians can confidently state that opioids have not demonstrated meaningful superiority over nonopioid analgesics for chronic pain and that the risk-benefit ratio worsens at higher doses and longer durations. The cannabinoid evidence, while promising for select neuropathic populations, does not yet support routine clinical recommendation outside of carefully structured treatment plans.

From a pharmacological standpoint, clinicians should be aware that the VA/DoD 2022 guideline now recommends buprenorphine over full mu-agonist opioids for patients already receiving daily opioid therapy, reflecting its ceiling effect on respiratory depression and lower abuse potential. Drug interactions between cannabinoids and common neurologic medications, including antiepileptics and antidepressants, warrant careful monitoring, though the truncated text limits full assessment of this topic. One concrete action clinicians can implement now is to ensure that every patient on opioid therapy has been offered naloxone, has been queried in the prescription drug monitoring program at each visit, and has a documented risk-benefit reassessment at regular intervals.

Study at a Glance

Study Type

Narrative CME review

Population

Adults with chronic noncancer pain, neuropathic pain, and headache disorders

Intervention

Opioid therapy and cannabinoid therapy for pain

Comparator

Nonopioid analgesics, placebo, and multimodal care (as cited in referenced trials)

Primary Outcomes

Pain intensity, physical function, risk-benefit assessment, adverse events

Sample Size

Not applicable (narrative review citing trials including a 96-RCT meta-analysis, n=26,169)

Journal

Continuum: Lifelong Learning in Neurology (AAN), Vol. 30(5), pp. 1447-1474

Year

2024

DOI or PMID

Not provided in available text

Funding Source

Not specified; authors report noncompensated and limited personal compensations

What Kind of Evidence Is This

This is a narrative clinical review published in the AAN’s continuing medical education journal, designed for practicing neurologists. It occupies a position below systematic reviews and meta-analyses in the evidence hierarchy because it does not employ a systematic literature search or predefined inclusion criteria. The most important inference constraint this imposes is that the selection and weighting of cited evidence reflects the authors’ expert judgment and may not be fully representative of the broader literature, introducing the possibility of citation bias even when the individual studies cited are themselves of high quality.

How This Fits With the Broader Literature

The review’s conclusions are broadly consistent with the direction of major clinical guidelines and landmark evidence syntheses from the past decade. Its citation of the Busse et al. (2018) meta-analysis of 96 RCTs aligns with the Cochrane Collaboration’s findings that opioids provide modest, short-term pain relief for chronic noncancer pain without clear long-term benefit. The emphasis on the harms of abrupt tapering reflects a growing body of observational research, including studies by Agnoli et al. and others demonstrating increased mortality following involuntary opioid dose reductions.

The review extends the conversation by placing cannabinoid evidence alongside opioid evidence in a single clinical framework, which remains relatively uncommon in neurology-focused reviews. This juxtaposition is timely given the rapid evolution of state-level cannabis regulations and increasing patient inquiries. The cannabinoid sections, to the extent they were available for analysis, appear consistent with the Cochrane reviews and AAN practice guidelines on cannabis-based medicines that have found modest efficacy signals for neuropathic pain with notable heterogeneity in study designs.

Common Misreadings

The most likely overinterpretation of this review is reading it as a blanket prohibition on opioids in neurologic pain practice. The review explicitly acknowledges that short-term opioid therapy may provide meaningful relief for specific conditions such as postherpetic neuralgia, and it strongly cautions against abrupt discontinuation in patients already on established therapy. Treating this review as justification for either initiating long-term opioids or for forcing rapid tapers would both misrepresent its central message. Similarly, the inclusion of cannabinoid evidence should not be read as an endorsement of cannabis-based therapies for routine clinical use; the review frames cannabinoids as investigational for most pain indications and notes their unlabeled status.

Bottom Line

This AAN review confirms that long-term opioid therapy for chronic neuropathic pain is generally not supported by current evidence and carries substantial, dose-dependent risks. It equally confirms that abrupt discontinuation of established opioid therapy is dangerous and should be avoided. Cannabinoids show promising but investigational signals for select neuropathic pain populations. For practice now, the actionable framework is nonopioid-first multimodal care for new patients, careful individualized management for those already on opioids, and transparent patient counseling about cannabinoids as evidence continues to develop.

References

1. Sandbrink F, Schuster NM. Opioids and cannabinoids for pain in neurologic practice. Continuum (Minneap Minn). 2024;30(5):1447-1474.
2. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain, United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95.
3. US Department of Veterans Affairs/Department of Defense. VA/DoD clinical practice guideline for the use of opioids in the management of chronic pain. Version 3.0. 2022.
4. Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA. 2018;320(23):2448-2460.
5. Agnoli A, Xing G, Tancredi DJ, Magnan E, Jerant A, Fenton JJ. Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA. 2021;326(5):411-419.